Deakin University
Browse
masand-designoftherapeutic-2020.pdf (9.93 MB)

Design of therapeutic antibody formulations for subcutaneous delivery

Download (9.93 MB)
thesis
posted on 2023-07-26, 03:02 authored by Girish M. Masand
Cetuximab is an anti-epidermal growth factor receptor (EGFR) monoclonal antibody approved for the treatment of head & neck cancer and colorectal cancer. The current administration of cetuximab is via intravenous infusion. Subcutaneous injections which does not require hospital stays is a preferred route by both patients and health care professionals. In a current study a stable high concentration formulation for cetuximab was developed, which has potential to be administered as subcutaneous injections for the cancer patients in future.

History

Pagination

301 p.

Open access

  • Yes

Language

English

Degree type

Doctorate

Degree name

Ph.D.

Copyright notice

All rights reserved

Editor/Contributor(s)

Jagat Kanwar, Arnab Kapat, Rupinder Kanwar, Colin Barrow

Faculty

Faculty of Health

School

School of Medicine

Usage metrics

    Theses

    Categories

    No categories selected

    Keywords

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC